Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced Death Ligand-Induced Apoptosis in Cutaneous SCC Cells by Treatment with Diclofenac/Hyaluronic Acid Correlates with Downregulation of c-FLIP
Lothar F. Fecker, Eggert Stockfleth, Frank Braun, et al.
Journal of Investigative Dermatology (2010) Vol. 130, Iss. 8, pp. 2098-2109
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
S Bacchi, Paola Palumbo, A.M. Sponta, et al.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (2012) Vol. 11, Iss. 1, pp. 52-64
Closed Access | Times Cited: 369
Diclofenac inhibits tumor necrosis factor‐α‐induced nuclear factor‐κB activation causing synergistic hepatocyte apoptosis
Lisa Fredriksson, Bram Herpers, Giulia Benedetti, et al.
Hepatology (2011) Vol. 53, Iss. 6, pp. 2027-2041
Open Access | Times Cited: 94
Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review
Domenico Arcuri, Brandon Ramchatesingh, François Lagacé, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4989-4989
Open Access | Times Cited: 21
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
Jing Zhao, Yixin Lü, Han‐Ming Shen
Cancer Letters (2011) Vol. 314, Iss. 1, pp. 8-23
Closed Access | Times Cited: 71
Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence
Karin Müller‐Decker
Cancer and Metastasis Reviews (2011) Vol. 30, Iss. 3-4, pp. 343-361
Closed Access | Times Cited: 70
Topical therapies for skin cancer and actinic keratosis
Tasnuva Haque, Khondaker Miraz Rahman, David E. Thurston, et al.
European Journal of Pharmaceutical Sciences (2015) Vol. 77, pp. 279-289
Open Access | Times Cited: 52
Validation of the 3D reconstructed human skin Comet assay, an animal-free alternative for following-up positive results from standardin vitrogenotoxicity assays
Stefan Pfuhler, Ralph Pirow, Thomas R. Downs, et al.
Mutagenesis (2020) Vol. 36, Iss. 1, pp. 19-35
Open Access | Times Cited: 44
New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel
Brian Berman
Clinical Cosmetic and Investigational Dermatology (2012), pp. 111-111
Open Access | Times Cited: 56
Combinatorial Effect of Non-Steroidal Anti-inflammatory Drugs and NF-κB Inhibitors in Ovarian Cancer Therapy
Luiz F. Zerbini, Rodrigo Esaki Tamura, Ricardo G. Correa, et al.
PLoS ONE (2011) Vol. 6, Iss. 9, pp. e24285-e24285
Open Access | Times Cited: 56
Indomethacin Sensitizes TRAIL-Resistant Melanoma Cells to TRAIL-Induced Apoptosis through ROS-Mediated Upregulation of Death Receptor 5 and Downregulation of Survivin
Anfernee Kai‐Wing Tse, Hui‐Hui Cao, Brian Chi‐Yan Cheng, et al.
Journal of Investigative Dermatology (2013) Vol. 134, Iss. 5, pp. 1397-1407
Open Access | Times Cited: 53
Down‐regulation of intracellular anti‐apoptotic proteins, particularly c‐FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL
Ali Hassanzadeh, Majid Farshdousti Hagh, Mohammad Reza Alivand, et al.
Journal of Cellular Physiology (2018) Vol. 233, Iss. 10, pp. 6470-6485
Closed Access | Times Cited: 43
Inhibitor of Apoptosis Proteins (IAPs) Limit RIPK1-Mediated Skin Inflammation
Holly Anderton, James Rickard, George A. Varigos, et al.
Journal of Investigative Dermatology (2017) Vol. 137, Iss. 11, pp. 2371-2379
Open Access | Times Cited: 40
Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Cutaneous T-Cell Lymphoma Cells and Enhance Their Sensitivity for TNF-Related Apoptosis-Inducing Ligand
Frank Braun, Nadya Al‐Yacoub, Michael Plötz, et al.
Journal of Investigative Dermatology (2011) Vol. 132, Iss. 2, pp. 429-439
Open Access | Times Cited: 42
Diclofenac gel in the treatment of actinic keratoses
Chris Nelson
Therapeutics and Clinical Risk Management (2011), pp. 207-207
Open Access | Times Cited: 40
Molecular Biology of Basal and Squamous Cell Carcinomas
Steffen Emmert, Michael P. Schön, Holger A. Haenssle
Springer eBooks (2014), pp. 234-252
Closed Access | Times Cited: 38
Monitoring Treatment of Field Cancerisation with 3% Diclofenac Sodium 2.5% Hyaluronic Acid by Reflectance Confocal Microscopy: A Histologic Correlation
Josep Malvehy, Rodrigo Roldán‐Marín, Pablo Iglesias-García, et al.
Acta Dermato Venereologica (2015) Vol. 95, Iss. 1, pp. 45-50
Open Access | Times Cited: 37
Adaptación española de la Guía europea para la evaluación y tratamiento de la queratosis actínica
Carlos Ferrándiz, E. Fonseca-Capdevila, Amaro García‐Diez, et al.
Actas Dermo-Sifiliográficas (2014) Vol. 105, Iss. 4, pp. 378-393
Closed Access | Times Cited: 34
Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis
Adrienne Maltusch, Joachim Röwert‐Huber, C. Matthies, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2011) Vol. 9, Iss. 12, pp. 1011-1017
Closed Access | Times Cited: 33
Treatment of actinic keratosis through inhibition of cyclooxygenase‐2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5%
Gareth J. Thomas, Pedro Herranz, Susana Balta Cruz, et al.
Dermatologic Therapy (2018) Vol. 32, Iss. 3
Open Access | Times Cited: 26
Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis
Katrin Singer, Katja Dettmer, Petra Unger, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 24
Validation of the 3D reconstructed human skin micronucleus (RSMN) assay: an animal-free alternative for following-up positive results from standardin vitrogenotoxicity assays
Stefan Pfuhler, Thomas R. Downs, Nicola J. Hewitt, et al.
Mutagenesis (2020) Vol. 36, Iss. 1, pp. 1-17
Open Access | Times Cited: 23
Improving the efficacy of photodynamic therapy for actinic keratosis: A comprehensive review of pharmacological pretreatment strategies
Celina Pihl, Catharina M. Lerche, F. Alan Andersen, et al.
Photodiagnosis and Photodynamic Therapy (2023) Vol. 43, pp. 103703-103703
Open Access | Times Cited: 7
Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses
Sven Quist, Harald Gollnick
Expert Opinion on Pharmacotherapy (2011) Vol. 12, Iss. 3, pp. 451-461
Closed Access | Times Cited: 28
Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid
Martina Ulrich, Giovanni Pellacani, Carlos Ferrándiz, et al.
European Journal of Dermatology (2014) Vol. 24, Iss. 2, pp. 158-167
Closed Access | Times Cited: 24
Ambivalent Effects of Tumor Necrosis Factor Alpha on Apoptosis of Malignant and Normal Human Keratinocytes
Georgios Kokolakis, Robert Sabat, Sabine Krüger‐Krasagakis, et al.
Skin Pharmacology and Physiology (2021) Vol. 34, Iss. 2, pp. 94-102
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top